Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.

ABSTRACT:

Background

Blood eosinophil counts and history of exacerbations have been proposed as predictors of patients with chronic obstructive pulmonary disease (COPD) who may benefit from triple therapy (inhaled corticosteroid, long-acting β₂-agonist and long-acting muscarinic antagonist).

Methods

In a retrospective cohort analysis we examined the profiles of COPD patients from the UK Clinical Practice Research Datalink (CPRD) and US Optum Clinformatics™ Data Mart (Optum) databases with reference to exacerbation frequency and blood eosinophil distribution.

Results

Of the 31,437 (CPRD) and 383,825 (Optum) patients with COPD, 15,364 (CPRD) and 139,465 (Optum) met the eligibility criteria and were included. Among patients with ≥2 exacerbations and available eosinophil

SUBMITTER: Vogelmeier CF 

PROVIDER: S-EPMC6686508 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature